07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

BNC105: Phase II data

Data from 136 evaluable patients with metastatic RCC who failed prior tyrosine kinase inhibitor (TKI) therapy in the Phase II portion of the open-label, dose-escalation, international Phase I/II DISRUPTOR-1 trial showed that IV BNC105 plus...
07:00 , Jul 27, 1998 |  BC Week In Review  |  Company News

Harvard Medical School other research news

Harvard researchers and colleagues published in Nature Genetics an association between a deletion in the A2M gene and increased risk of developing AD (p=0.001). A2M is thought to be involved in the clearance of beta-amyloid...